CPC A61K 31/4172 (2013.01) [A61P 27/02 (2018.01)] | 12 Claims |
1. A method for alleviating and preventing age-associated vitreous degeneration in a mammal, comprising administrating to the mammal in need thereof a therapeutically effective amount of L-ergothioneine, or an analog thereof, or a pharmaceutically acceptable salt, acid, ester, polymer, or an analog thereof, as an active ingredient, wherein L-ergothioneine is administrated in the form of eyedrops or spongarion, and the administration of L-ergothioneine is capable of scavenging chronic reactive oxygen species directly and radically to mitigate and prevent HA depolymerization and HA decreasing-viscosity in the mammal's vitreous body, resulting in an increased vitreous gel content in a mammal's eye.
|